-+ 0.00%
-+ 0.00%
-+ 0.00%
Nippon Shinyaku secures US commercialization rights for AB2 Bio’s Tadekinig alfa
Share
Listen to the news
Nippon Shinyaku secures US commercialization rights for AB2 Bio’s Tadekinig alfa
  • Nippon Shinyaku exercised option rights under its January 2025 agreement with AB2 Bio to commercialize Tadekinig alfa in the U.S.
  • Deal grants exclusive U.S. commercialization rights for monogenic IL-18 driven hyperinflammatory syndrome in patients with NLRC4 and XIAP mutations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending